Share on StockTwits

ADMA Biologics (NASDAQ:ADMA) CEO Adam S. Grossman bought 1,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average cost of $9.50 per share, with a total value of $9,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ADMA Biologics (NASDAQ:ADMA) traded up 1.08% during mid-day trading on Tuesday, hitting $9.35. 5,700 shares of the company’s stock traded hands. ADMA Biologics has a one year low of $6.52 and a one year high of $10.75. The stock’s 50-day moving average is $9.93 and its 200-day moving average is $8.87. The company’s market cap is $86.9 million.

Separately, analysts at Maxim Group reiterated a “buy” rating on shares of ADMA Biologics in a research note on Friday, July 11th. They now have a $15.00 price target on the stock.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.